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I. Executive Summary
The Joint Standing Committee on Insurance and Financial Services (Committee) of the 126th
Maine Legislature directed the Bureau of Insurance (Bureau) to review LD 1600, An Act to
Require Health Insurers to Provide Coverage for Human Leukocyte Antigen Testing to Establish
Bone marrow Donor Transplantation Suitability. The review was conducted as required by Title
24-A, Section 2752. This document and review is a collaborative effort of NovaRest, Inc., an
actuarial consulting firm, and the Bureau.
LD 1600 requires that all health insurance policies provide coverage for laboratory fees arising
from human leukocyte antigen (HLA) testing performed to establish bone marrow
transplantation suitability, up to $150.
The bill provides “(2) Prohibition. A testing facility may not bill, charge, collect a deposit from,
seek payment or reimbursement from or seek recourse against an individual covered under the
policy or contract or a person acting on behalf of the individual for any portion of the laboratory
fees.” We are uncertain regarding the intent of this provision. First, because insurance carriers
are only required to cover laboratory fees up to $150 the bill appears to prohibit testing facilities
from charging more than $150. We note the Bureau of Insurance does not typically regulate
testing facilities and the $150 limitation would be especially difficult to enforce against out-ofstate testing facilities. Second, if the intent is to require insurance coverage of the testing with
no cost-sharing, we would suggest language requiring the insurance contract to cover without
applying the deductible, coinsurance or copays.
For patients diagnosed with leukemia, lymphoma and other life-threatening diseases, a bone
marrow or cord blood transplant may be their best or only hope for a cure. However,
approximately 70% of patients who need a transplant do not have a matching donor in their
1
family. Outcomes of unrelated donor transplants are approaching the rates of related donor

transplants. In 2010, overall survival rates at one year were 71 percent (unrelated donor) and 78
2
percent (related donor). Because the Bone Marrow Donor Worldwide Registry (BMDW) now

comprises over six million HLA-typed volunteer donors, the chance of identifying an HLA
serologically identical donor has increased dramatically.

3

1

Be the Match, How We Help Patients, Accessed 1/18/14, http://bethematch.org/About-Us/How-we-help-patients/
U.S. Department of Health and Human Services, Understanding bone marrow and cord blood transplants, Accessed 1/28/14,
http://bloodcell.transplant.hrsa.gov/transplant/understanding_tx/transplant_faqs/index.html#Survival_unrelated_related
3
Bone Marrow Transplantation, Unrelated Donor Identification, Accessed 1/18/14,
http://www.nature.com/bmt/journal/v26/n4/full/1702529a.html
2
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Bone marrow screening tests are not included in the State’s essential benefits package or the
essential health benefits (EHBs) set by the Affordable Care Act, but transplant coverage is.
Currently, most insurance carriers do provide coverage for potential donor screening testing
done for a particular recipient. The proposed mandate would extend coverage to testing
without a potential transplant recipient.
The National Organ Transplant Act (NOTA) in 1984, led to the creation of the National Bone
Marrow Donor Registry (NBMDR) in 1987. Funding for the Registry comes from both military
(Navy) and civilian (National Institutes of Health) branches of the federal government.
Potential donors without insurance coverage for the screening test may get tested for free at a
NMDP bone marrow drive or through a free mail-in kit. The free tests are supported by
donations or funding from NMDP. As of July 2009, the national Bone Marrow Transplant Registry
in the US began to offer free registration testing to those potential unrelated donors that sign up
for the transplant registry.
The “Be The Match” website states the target recruiting ages for new registry members is 18 to
44. “This is based on medical research that shows younger donors are best for patients and
provide the greatest chance for transplant success,” the website explains. “Because of this,
doctors request donors in the 18 to 44 age group over 90% of the time.” Individuals ages 45 to
60 who want to join the bone marrow registry must do so online and will be asked to make a
$100 payment to cover expenses. Currently much of the testing is funded through nonprofit
organizations or fund raising, but that funding is not guaranteed in the future.
NovaRest, an actuarial consulting firm hired by the Bureau, estimated the premium increase to
be $0.01 per member per month (PMPM) if there is cost sharing and $0.02 PMPM if no cost
sharing is allowed based on $125 average cost for the testing. The Affordable Care Act (ACA)
requires States to defray the cost of mandated benefits not included in the Essential Health
Benefits (EHB). The estimated increased coverage due to this mandate would be approximately
$48,000 per year.

2
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II. Background
The Joint Standing Committee on Insurance and Financial Services (Committee) of the 126th
Maine Legislature directed the Bureau of Insurance (Bureau) to review LD 1600, An Act to
Require Health Insurers to Provide Coverage for Human Leukocyte Antigen Testing to Establish
Bone Marrow Donor Transplantation Suitability. The review was conducted as required by Title
24-A, Section 2752. This document and review is a collaborative effort of NovaRest, Inc., an
actuarial consulting firm, and the Bureau. In addition to the statutory criteria, the Committee
asked that the review provide an analysis of:

•

The extent to which coverage of bone marrow screening tests are included in the State’s
essential benefits package and covered by existing health plans, including whether
carriers put a limit on the number of potential donors who are provided coverage for
screening tests;

•

Whether existing health care plans provide coverage for laboratory fees associated with
donor drives or other widespread testing of unrelated donors;

•

Whether copayments, deductibles or other cost-sharing requirements are imposed on
existing coverage and, if this bill were enacted, an analysis of the financial impact of an
allowance for cost-sharing compared to coverage without cost-sharing;

•

Whether there are any comparative research studies documenting the potential savings
in health care costs through facilitating bone marrow transplantation versus other
treatments;

•

If the bill expands coverage beyond the essential benefits package, the estimated costs to
the State to defray the costs of including the coverage in qualified health plans; and

•

Information on the estimated and actual costs of providing this coverage in the other
New England states that have enacted similar laws, including information on whether
initial costs of coverage may have moderated since enactment.

LD 1600 requires that all individual, group health and health maintenance organization (HMO)
insurance policies provide coverage for laboratory fees up to $150 arising from human leukocyte
antigen testing performed to establish bone marrow transplantation suitability in accordance
with the following requirements:
A. The individual covered under the policy or contract must meet the criteria for testing
established by the National Marrow Donor Program, or its successor organization;

3
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B. The testing must be performed in a facility that is accredited by a national accrediting
body with requirements that are substantially equivalent to or more stringent than those of
the College of American Pathologists and is certified under the federal Clinical Laboratories
Improvement Act of 1967, 42 United States Code, Section 263a; and
C. At the time of the testing, the individual covered under the policy or contract must
complete and sign an informed consent form that authorizes the results of the test to be
used for participation in the National Marrow Donor Program, or its successor organization,
and acknowledges a willingness to be a bone marrow donor if a suitable match is found.
The bill provides “(2) Prohibition. A testing facility may not bill, charge, collect a deposit from,
seek payment or reimbursement from or seek recourse against an individual covered under the
policy or contract or a person acting on behalf of the individual for any portion of the laboratory
fees.” We are uncertain regarding the intent of this provision. First, because insurance carriers
are only required to cover laboratory fees up to $150 the bill appears to prohibit testing facilities
from charging more than $150. We note the Bureau of Insurance does not typically regulate
testing facilities and the $150 limitation would be especially difficult to enforce against out-ofstate testing facilities. Second, if the intent is to require insurance coverage of the testing with
no cost-sharing, we would suggest language requiring the insurance contract to cover without
applying the deductible, coinsurance or copays.
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are
procedures that restore stem cells that have been destroyed by high doses of chemotherapy
and/or radiation therapy, due to disease. There are three types of transplants:
o

In autologous transplants, patients receive their own stem cells.

o

In syngeneic transplants, patients receive stem cells from their identical twin.

o

In allogeneic transplants, patients receive stem cells from their brother, sister, or parent.
A person who is not related to the patient (an unrelated donor) also may be used. 4

The requirements of LD 1600 will potentially increase the number of matched patients to
suitable donors. Every four minutes someone is diagnosed with a blood cancer, like leukemia.
5
For many, their only hope for a cure is a bone marrow transplant. Matching a patient with a

4

National Cancer Institute, Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation, Accessed 1/29/14,
http://www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant
5
Be the Match, Transplant Basics, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/
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6

donor is much more complex than finding two people with the same blood type. The donor’s
stem cells must have similar genetic markers as the patient’s. These markers are called human
leukocyte antigens or HLA type.

7

The common procedure in searching for a bone marrow donor for a particular patient is first to
examine the patient’s parents, brothers, and sisters in search of an HLA-identical donor. If no
identical individuals are found, then the search is begun for an unrelated donor.

8

Doctors look for a donor with a close HLA match to the patient. This close HLA match is the most
important factor in finding the best donor for a patient.

9

The National Organ Transplant Act (NOTA) in 1984, led to the creation of the National Bone
Marrow Donor Registry in 1987. Start-up funding for the Registry came from both military
(Navy) and civilian (National Institutes of Health) branches of the federal government.
The National Marrow Donor Program (NMDP) requires evaluation of donor-recipient
histocompatibility matching prior to unrelated hematopoietic cell transplantation (HCT). The
minimum acceptable match was originally defined by serologic splits (antigen level of resolution)
at these 3 loci (6 possible antigens) and required at least 5 matches, that is, a 5 of 6 match. This
requirement has changed little over the years. Currently, to request a donor for transplantation,
the minimal acceptable level of matching remains a 5 of 6 match for a HLA donor.
In 1990, the NMDP became a separate private nonprofit organization in Minneapolis, and was
contracted by Health and Human Services (HHS) to operate the registry, replacing the Red Cross.
Responsibility for maintaining the public US BMT donor registry resides with the Division of
Transplantation of the Healthcare Systems Bureau of the Health Resources & Services
Administration (HRSA) of HHS. HRSA does not operate the registry itself, but contracts out the
federally-funded service. For the renewal to occur each time, Congress must pass enabling
legislation that is then signed into law by the President. To date, at each renewal, the registry
contract has been awarded to the NMDP. The Office of Naval Research continues to fund
scientific research and minority donor testing, conducted by the NMDP.
6

Be the Match, Matching patients with donors, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/Matching-patientswith-donors/
7
Blood & Marrow Transplant Information Network, Finding a Donor, Accessed 1/28/14,
http://www.bmtinfonet.org/before/findingdonor
8
American Society of Hematology, Blood, Accessed 1/28/14,
http://bloodjournal.hematologylibrary.org/content/87/2/800.full.pdf
9
Be the Match, Matching patients with donors, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/Matching-patientswith-donors/
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Legislation in 1991 led to the first allocation of federal funds for donor typing. Continued citizen
efforts to include the recruitment of donors from under-represented racial/ethnic groups as a
program priority, led to new NMDP recruitment programs starting in the mid-90s, when existing
ethnic-specific recruitment groups were incorporated into the NMDP Network for the first
time.

10

Some money for the Bone Marrow Screening Fund has come from the voluntary contribution
check off on tax forms in Maine. This was recently eliminated. Other local funding comes from
the recipient, through family and friends raising money for donor drives. Michael’s Fund and the
Maine Leukemia Foundation help fund donors as well.
More than 17,900 bone marrow transplants were performed in the United States in 2011a.
Number of
Transplants
a
Performed

Type of Transplant

10,403b

Autologous
(the cells for transplant were provided by the patient)

3,114

Related allogeneic
(the cells for transplant were provided by the patient's sibling
or another family member)

4,421

Unrelated allogeneic
(the cells for transplant were provided by a volunteer donor)

a. These data are of transplants performed from January 1, 2008 through December 31, 2011. These data were reported to the
Center for International Blood and Marrow Transplant Research® (CIBMTR).
b. Many U.S. transplant centers voluntarily report autologous transplant data to the CIBMTR. Because these data are not required to
be reported, this number represents only a portion of the actual autologous transplants performed. 11

The extent to which coverage of bone marrow screening tests are included in the State’s
essential benefits package and covered by existing health plans, including whether carriers put
a limit on the number of potential donors who are provided coverage for screening tests;
Currently, bone marrow screening tests are not included in the State’s essential benefits
package or the essential health benefits (EHBs) set by the Affordable Care Act, but transplant

10

http://bmtbasics.org/basics-2/finding-a-donor/donor-registries-background/
Health Resources and Services Administration, General Frequently Asked Questions, Accessed 1/29/14,
http://bloodcell.transplant.hrsa.gov/ABOUT/General_FAQs/index.html

11
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coverage is. Historically, when an insured is covered for a transplant, donor testing is covered at
least for the patient’s immediate family.
Anthem and Maine Community Health Options (MCHO) cover donor testing of unrelated donors
under an insured member’s policy if their insured needs a transplant that has been determined
to be medically necessary and there is no suitable familial match. They do not provide testing of
unrelated donors under the potential donor’s policy. There is no limit to the number of
individuals covered for testing.
MEGA stated that their health benefit plans do not provide benefits to address the coverage for
the cost of testing for bone marrow donation suitability.
Aetna responded that they only cover immediate family members.
Whether existing health care plans provide coverage for laboratory fees associated with donor
drives or other widespread testing of unrelated donors;
If a covered individual requires a transplant, typically the individual’s insurer will cover the
testing of family members and other volunteer donors for the insured individual.
Aetna, Cigna, Maine Community Health Options and MEGA do not provide coverage for donor
drives or other widespread testing of unrelated donors.
Harvard Pilgrim’s policy is that bone marrow donation is included in organ donor protocols. The
plan will cover evaluation of donor organ for tissue (histologic) HLA testing, compatibility and
has no limits on how many tests. They will also cover donor drives if they are billed.
Cigna covers individuals being tested as donors for one of its members. The recipient’s level of
coverage would be specific to their plan and transplant benefits.
Anthem responded that their medical policy does not specifically address donor drives but
testing at such a drive would likely be covered, if authorized as medically necessary, and if the
tests were submitted by a participating provider.
Whether copayments, deductibles or other cost-sharing requirements are imposed on existing
coverage and, if this bill were enacted, an analysis of the financial impact of an allowance for
cost-sharing compared to coverage without cost-sharing

7

th

LD 1600, 126 Maine State Legislature
An Act to Require Health Insurers to Provide Coverage for Human Leukocyte Antigen
Testing to Establish Bone Marrow Donor Transplantation Suitability

Depending on deductible levels and copays the cost sharing can range from 0% to 100%. The
financial impact would increase if there was no cost sharing, but since the total cost is estimated
to be minimal, the added cost would be minimal. We estimate a financial impact of $0.01 permember-per-month (PMPM) with cost sharing and $0.02 PMPM if no cost sharing is allowed.
Aetna responded that based on Maine’s historical experience and the historical experience of
other Northeast states with HLA mandates, they believe that implementing this proposed level
of coverage, with and without cost-sharing, would generate an immaterial increase in premiums,
administrative expenses and indirect costs.
Cigna responded that the financial impact really does depend on the plan design and level of
cost share, but in general the expectation is that the impact would be minimal across all types of
costs referenced.
Anthem responded that they estimate a claims cost of $0.034 PMPM, which would drive a
minimal impact on premiums. They do not anticipate an impact on administrative expenses.
Whether there are any comparative research studies documenting the potential savings in
health care costs through facilitating bone marrow transplantation versus other treatments
There are medical studies quantifying effectiveness for various aspects of types of treatments.
An article provided by the National Marrow Donor Program (NMDP) concluded that “the time
taken from diagnosis to transplant is recognized to adversely affect patient outcome, and
provision of unrelated donors has been identified as a key source of delay.”

12

The article

identified areas in need of improvement to shorten the time a donor would be available such as
recruiting from ethnic minority groups, donor registries may need to increase the number of
new donors typed to high resolution for better matches and moving towards better donor
quality instead of just high numbers of donors.
13
Also an article in the publication Stem Cells analyzed five studies on the cost-effectiveness and

third-party charges of bone marrow transplants. The conclusion was that related matches are
the most cost-effective procedure for many diseases, however, they felt that future treatment
advances would increase the cost-effectiveness of unrelated transplants.

12

Bone Marrow Transplantation (2013) 48, 210-219
Westerman, I. L. and Bennett, C. L. (1996), A Review of the Costs, Cost-Effectiveness and Third-Party Charges of Bone Marrow
Transplantation. Stem Cells, 14: 312–319. doi: 10.1002/stem.140312
13
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If the bill expands coverage beyond the essential benefits package, the estimated costs to the
State to defray the costs of including the coverage in qualified health plans
We estimate the cost to the state beyond the essential benefits package would be less than
$48,000 a year.
Information on the estimated and actual costs of providing this coverage in the other New
England states that have enacted similar laws, including information on whether initial costs
of coverage may have moderated since enactment.
In Anthem’s initial response they indicated “of the four states identified, there are Anthem Plans
in New Hampshire and Connecticut. Looking at Maine, New Hampshire, and Connecticut
Anthem’s analysis indicates a cost of $0.034 per member per month.”
Connecticut’s cost impact did not vary significantly over the past three years. The total
projected cost remained at $0.05 PMPM for that period. While Connecticut does not cap the
reimbursement it does not allow the cost share to exceed 20% of the cost of the test. Anthem
provided the following table of number and cost of claims for Connecticut and New Hampshire.

Connecticut:
Year
Claim Count
Paid Claims

New Hampshire:
Year
Claim Count
Paid Claims

2011
637
$27,748

2012
930
$36,687

2013
693
$27,434

Average
753
$30,623

2011
287
$21,644

2012
362
$18,153

2013
265
$13,528

Average
305
$17,775

Anthem noted significantly higher expenses for screening tests in New Hampshire of about $0.26
PMPM in 2010. At that time New Hampshire did not have a cap in place and there were abuses
by the facility and registry documented by the New Hampshire Attorney General in February
2012. Insurance companies were billed between $700 and $4,300 for tests that cost a fraction
of those amounts.

14

Cigna responded by saying “since it is already standardly covered by Cigna, our pricing team says
the mandate would not have a notable impact on costs. Other than the issue in New Hampshire
14

Press Release, New Hampshire, Department of Justice, Office of the Attorney General, February 2, 2012
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where the donor organization was investigated by the attorney general, similar mandates in
other states have not been a big issue to Cigna.”
Final review by CIGNA of the 2013 claim data in New Hampshire continues to show utilization is
low for insured business. As they had only 21 claims for HLA screening in 2013, it would be
difficult to determine if it costs have moderated since enactment or to predict if there will be
increases. It seems to reason that very aggressive recruiting in bone marrow donor drives would
likely increase utilization but that would not be predictable. The range of the 21 charges
submitted to Cigna for the 2013 claims was $49-$337. These billed charges totaled $4,431.66
and Cigna paid $1,741.66 for HLA screening in 2013. Typically Cigna paid less than the billed
charges due to contracted rates and in all cases but one, Cigna paid less than $150. The range of
paid claims was $16.56 to $149.40, with one charge paid at $161.66. Member cost share
(coinsurance, copay, deductible) was $0 with the exception of one member who paid $27.59
toward a deductible.
Harvard Pilgrim noted they “cannot provide costs and volumes before and after the mandate.
Anecdotally we have not seen utilization spike dramatically, but we were providing coverage for
the test prior to the mandate in New Hampshire so it isn’t clear how the mandate impacted
behavior.”
Compass Health Analytics, an actuarial consulting firm, prepared a review of state-mandated
health insurance benefits for the Commonwealth of Massachusetts in January 2013. In their
report they estimated the premium impact of the HLA mandate to be $0.0055 or 0%.

10
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III. Social Impact
A.
1.

Social Impact of Mandating the Benefit
The extent to which the treatment or service is utilized by a significant portion of the
population.

Nationally, each year, nearly 20,000 people age 0-74 years might benefit from a potential life–
saving bone marrow transplant.

15

The NMDP Network has more than four million volunteer donors and has Donor Centers and
Transplant Centers in 14 countries. About 40% of the transplants facilitated by the NMDP
involve either a U.S. patient receiving bone marrow and/or stem cells from an international
donor, or an international patient receiving bone marrow/stem cells from a U.S. donor. The
NMDP coordinates more than 130 stem cell transplants each month.

16

This year, more than 130,000 Americans will be diagnosed with a serious blood disease.
Leukemia (a blood cancer) will strike 44,000 Americans this year, including 3,500 children. It will
kill about half of the adults and about 700 of the children.

17

Testimony indicated that in Maine between 1,000 to 2,000 people are tested for donor
compatibility each year, at a cost of $100 to $150 per test. In 2012 1,600 donors joined the
registry in Maine. According to the Bone Marrow Donor Program, since its inception 226
Mainers have become donors and 263 have received transplants. Most of those have taken
place in the past ten years.
2.

The extent to which the service or treatment is available to the population.

HLA testing is available at donor centers, online and through donor drives.
There are currently no NMDP Donor Centers in Maine, however, the following Donor Centers
cover all or part of Maine.

15

Health Resources and Services Administration, How many people need a bone marrow transplant?, Accessed 1/29/14,
http://bloodcell.transplant.hrsa.gov/about/general_faqs/index.html
16
Surgey.com, Bone Marrow Transplantation, Accessed 1/29/14, http://www.surgery.com/procedure/bone-marrowtransplantation/demographics
17
Institute for Justice, Bone Marrow Statistics, Accessed 1/29/14, http://ij.org/bone-marrow-statistics
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Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
(617) 632-2561
(866) 875-3324
http://www.dfci.org/nmdp
The HLA Registry
A Division of Community Blood Services
102 Chestnut Ridge Road
Montvale, NJ 07401
(201) 389-0480
(800) 336-3363
http://www.communitybloodservices.org
National Marrow Donor Program Northeast District
700 Spring Garden Street
Philadelphia, PA 19123-3594
(877) 868-8010
(877) 868-8010
http://www.BeTheMatch.org

3.

The extent to which insurance coverage for this treatment is already available.

Aetna considers compatibility testing of prospective donors who are members of the immediate
family (first-degree relatives, i.e. parents, siblings and children) and harvesting and short-term
storage of peripheral stem cells or bone marrow from the identified donor medically necessary
when an allogeneic bone marrow or peripheral stem cell transplant is authorized by Aetna.
Aetna does cover testing of immediate family members.
Harvard Pilgrim’s policy is that bone marrow donation is included in organ donor protocols. The
plan will cover evaluation of donor organ for tissue (histologic) HLA testing, compatibility and
has no limits on how many tests. They also will cover the cost for donor drives, if billed.
Cigna covers screening if the recipient is in transplant case management and is part of the
Lifesource contracts.
Anthem covers testing of unrelated donors if there is not a suitable familial match and the
insured needs a transplant that has been determined to be medically necessary.

12
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4.

If coverage is not generally available, the extent to which the lack of coverage results in
a person being unable to obtain the necessary health care treatment.

Lack of a substantial number of potential donors available on the National Registry could lead to
delays in treatment for the recipient of the transplant. Without insurance coverage the $100
cost for the screening test could deter potential donors.
The Dana-Farber website states: “If your insurance will not cover the tissue-typing fee, we are
able to cover the cost of your test. However, if you would like to make a tax-deductible donation
to help our recruitment efforts, we would greatly appreciate it.”
Without health insurance covering the cost of testing, either the donor’s funds or donations are
used to pay for the swab testing. According to written testimony by Steven and Lisa Cota when
Steve’s lifelong friend Gregory, “Gregg” Sanborn needed a transplant they had to turn to
donations to defray the costs. “As a result of this effort to find a donor and promote the need
for donors, over a thousand people were added to donor roles.”
In his testimony Patrick Roy stated “everyone should want the chance to save a life, and they
should have that opportunity. At the time of my swab test, if I had had to cover the $100 swab
test, unfortunately I would not have done so.”
According to testimony by Todd Ellison “having bone marrow testing covered by insurers (thus
alleviating the burden of cost to those tested) will allow a greater number of people to be tested
and added to the roles of potential bone marrow donors. Increasing the number of possible
donors will ultimately result in increasing the number of “matches” for bone marrow
transplantation.
5.

If coverage is not generally available, the extent to which the lack of coverage involves
unreasonable financial hardship.

The lack of insurance coverage for the initial test may be a deterrent for individuals that might
otherwise be willing to be tested. Patients who are diagnosed with cancer and need a bone
marrow transplant may be faced with covering the cost associated with the initial testing
themselves, multiplied times many individuals and tests. In most cases the insurance of an
insured patient will cover the testing of at least family members and potentially unrelated
potential donors. If the insurance does not cover needed testing, the potential cost for a patient
paying could be high.

13
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Many cheek swab tests range in price from $100 to $150. A prospective donor can also order a
cheek swap kit from various non-profit organizations. There are organizations such as Swab a
Cheek and Cheekswab that are dedicated to increase the number of donors. However, if these
organizations do not receive adequate funding they may not be able to continue.
As John P. Gallivan testified, “It is a shame that families like mine are forced to spend an
exorbitant amount of money just to find a match. We didn’t want people to be hesitant to get
tested in Wethersfield, so with the help of our friends we covered the cost of the drive
ourselves.”
6.

The level of public demand and the level of demand from providers for this treatment or
service.

During the public hearing for LD 1600, advocates for this bill testified about the battle to find
suitable donors and the need to defray the cost for those willing to enter the registry. There are
advocacy groups dedicated to increasing public awareness about registering to become a bone
marrow donor.
Demand for this benefit comes “primarily from prospective recipients and their families and
from the National Marrow Donor Program. The NMDP indicated they receive approximately
1,200 new requests for registry searches per month nationally. One study in 2001 indicated that
approximately 15 percent of patient searches do not find a match.”
7.

18

The level of public demand and the level of demand from the providers for individual or
group coverage of this treatment.

In testimony from Patricia Lang, the director of the Rhode Island Blood Center she stated that
with the insurance mandates in the New England states their file of registered potential donors
has grown from 35,000 to 95,000
8.

The likelihood of meeting a consumer need as evidenced by the experience in other
states.

Evidence in other states is limited. Rhode Island, Massachusetts, Missouri and New Hampshire
18

Review and Evaluation of Public Act 09-188, An Act Concerning Wellness Programs and Expansion of Health Insurance
Coverage, University of Connecticut, December 2009.
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have already passed similar legislation. Even with the support of the insurance mandate,
though, less than 50% of those taking the screening test have insurance coverage.
9.

The relevant findings of the state health planning agency or the appropriate health
system agency relating to the social impact of the mandated benefit.

State agencies did not provide findings pertaining to the proposed legislation.
10.

The alternatives to meeting the identified need.

Close relatives, especially brothers and sisters, are more likely than unrelated people to be HLAmatched. However, only 25 to 35 percent of patients have an HLA-matched sibling.

19

The alternative for the health insurance company paying for coverage is that most patients will
reach out to friends, family, non-profit organizations and even employers to help defray the cost
of testing when willing participants cannot afford the $100-$150. Per the testimony of Steven
Cote “family, friends and communities banded together to host stem cell donor drives: monies
were donated to pay for those who wanted desperately to help in some way but could not
afford the $100 fee for the non-invasive swab test.”
11.

Whether the benefit is a medical or a broader social need and whether it is inconsistent
with the role of insurance and the concept of managed care.

HLA testing required by LD 1600 does not meet a medical need for the person being tested as a
potential donor. The coverage is not inconsistent with the role of insurance to provide medically
necessary services for a condition. However this mandate may step outside of the role of
insurance in that it requires providers to pay for testing to establish bone marrow donor
transplantation suitability unrelated to the need of an insured member. It is unusual for health
insurance companies to reimburse for a test that will not necessarily benefit their insured. For
example, Aetna already covers the cost of family member testing. The testing is provided for a
person who needs a transplant, and not for potential future use.
It is possible that the passing of this legislation will meet a broader social need in that it would
encourage more individuals to get tested and be available as donors. This outcome would have
the potential to assist more patients in need of life-saving bone marrow transplants. At any
19

National Cancer Institute, Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation,
Accessed 1/29/14, http://www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant
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given time, about 7,500 American are actively searching the national registry for an unrelated
donor. Only 2 percent of the population is on the national registry. At least 1,000 people die
each year because they cannot find a matching donor.

20

The benefit is reduced since a significant number of those on the national bone marrow registry
cannot be located or will not donate when asked to do so. The percentages of donors who are
available and willing are: 65 percent for Caucasians; 47 percent for Hispanics; 44 percent for
Asians; 34 percent for African-Americans.
12.

The impact of any social stigma attached to the benefit upon the market.

There is no known social stigma associated with being tested as a potential donor.
13.

The impact of this benefit upon the other benefits currently offered.

This legislation could impact the number of transplants performed, if it results in more donor
matches.
14.

The impact of the benefit as it relates to employers shifting to self-insurance and the
extent to which the benefit is currently being offered by employers with self-insured
plans.

As premiums increase due to mandated benefits, some employers choose to self-insure in order
to have more control over the benefits they provide to employees and to control the cost of
premiums. We cannot estimate the impact on premiums, but believe there would be no shifting
to self-insured plans.
15.

The impact of making the benefit applicable to the state employee health insurance
program.

Aetna’s analysis indicates that the impact would be immaterial.

20

Institute for Justice, Op cit.
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IV. Financial Impact
B.
1.

Financial Impact of Mandating Benefits
The extent to which the proposed insurance coverage would increase or decrease the
cost of the service or treatment over the next five years.

If the service is covered by insurance it is logical to expect the increase in demand and
availability of insurance coverage to increase the cost of the service. It is also possible that the
mandate could lead to new testing technologies that may be more expensive and increase the
overall cost of the service. Since this act covers $150 per service, we expect that the cost will
increase to that amount, especially if insured cost sharing is not allowed.
2.

The extent to which the proposed coverage might increase the appropriate or
inappropriate use of the treatment or service over the next five years.

Since there will be less or no upfront cost it may be more likely that an individual is willing to get
tested, but unwilling to make the potentially lifesaving donation should the need arise. As
reported by the Institute of Justice “a significant number of those on the national bone marrow
registry cannot be located or will not donate when asked to do so.”

21

The collection of marrow

is not a simple matter and involves recovery and loss of work time.
Even if all potential donors do not go through with the actual donation, it is reasonable to
believe that the increase in matches will have a positive impact on the number of actual
transplants that take place. How many of these transplants will be for citizens of Maine rather
than patients matched in other states, or other countries, is unknown.
3.

The extent to which the mandated treatment or service might serve as an alternative for
more expensive or less expensive treatment or service.

Currently, there are no other widely used methods to the current HLA screening test to match
potential donors with patients that need hematopoietic stem cell transplants.
4.

The methods which will be instituted to manage the utilization and costs of the proposed
mandate.

21

Institute for Justice, Op cit.
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Typically an insurance company can limit covered services to those that are medically necessary
for their members, but LD 1600 would not necessarily be for the benefit of the insured. The
mandate for the HLA testing may result in carriers negotiating with preferred labs for the
reimbursement for HLA tests. Anthem suggested that the legislation include a provision that
allows a carrier to require the use of certain codes specified by the carrier for reimbursement.
This would help to ensure the claims are properly adjudicated and avoid issues that have
occurred in the past in other states.
5.

The extent to which insurance coverage may affect the number and types of providers
over the next five years.

The mouth swab test can be self-administered at home and with the usage in Maine limited to
1,000 to 2,000 tests a year we do not foresee any new providers to process the tests in the next
five years.
6.

The extent to which the insurance coverage of the health care service or providers may
be reasonably expected to increase or decrease the insurance premium or administrative
expenses of policyholders.

Aetna did indicate “reimbursement for donor fairs would be administratively difficult if the
claims are not submitted through a provider or entity that can submit claims electronically.
Unum testified “as drafted, however, Unum is concerned that LD 1600 would include its
supplemental critical illness insurance that has been exempt from the definition of health
insurance with respect to mandated benefits and coverage laws, see Title 24-A MRSA 704(2),
since that law was enacted in 2001.” If this were true, the cost of this type of insurance would
also increase.
Aetna Response: “Based on Maine’s historical experience and the historical experience of other
Northeast states with HLA coverage mandates, we believe that implementing this proposed
level of coverage, with and without cost-sharing, would generate an immaterial increase in
premiums, administrative expenses and indirect costs.”
Cigna Response: “The financial impact really does depend on the plan design and level of cost
share, but in general the expectation is that the impact would be minimal across all types of
costs referenced.”
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NovaRest, an actuarial consulting firm, estimated the premium increase to be $0.01 PMPM if
there is cost sharing and $0.02 PMPM if no cost sharing is allowed.
7.

The impact of indirect costs, which are costs other than premiums and administrative
costs, on the question of the cost and benefits of coverage.

There will not be any additional cost effect beyond benefit and administrative costs.
8.

The impact on the total cost of health care, including potential benefits and savings to
insurers and employers because the proposed mandated treatment or service prevents
disease or illness or leads to the early detection and treatment of disease or illness that is
less costly than treatment or service for later stages of a disease or illness.

An article provided by the National Marrow Donor Program (NMDP) concluded that “the time
taken from diagnosis to transplant is recognized to adversely affect patient outcome, and
provision of unrelated donors has been identified as a key source of delay.”

22

According to testimony by Steve Cote “the number of registered donors will also multiply,
leading to further matches and lives saved moving forward.” There is potentially a savings if a
patient is matched with a donor sooner and medical costs that would take place between the
need for a transplant and the actual transplant are eliminated.
In testimony by Ellen Guilford she stated, “I truly believe had he had a donor back in March or
April, Gregg’s body and immune system would not have been so ravaged and it would have been
easier for him to fight the infection that often accompanies receiving a donation. It is having a
registry full of potential donors waiting to help ‘us’ when we are in need that will ultimately save
lives.”
9.

The effects of mandating the benefit on the cost of health care, particularly the premium
and administrative expenses and indirect costs, to employers and employees, including
the financial impact on small employers, medium-sized employers and large employers.

The cost of healthcare will increase to the extent that more tests are administered and the cost
per test is increased. Currently much of the testing is funded through nonprofit organizations,
but that funding is not guaranteed in the future. To the extent that insurance coverage replaces

22

Bone Marrow Transplantation (2013) 48, 210-219
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the nonprofit efforts, it will not impact the total cost of health care.
We estimate the impact on premium to be between $0.01 and $0.02 PMPM.
10.

The effect of the proposed mandates on cost-shifting between private and public payers
of health care coverage and on the overall cost of the health care delivery system in this
State.

To the extent that these services are currently covered by MaineCare and will be paid for by
private insurance after the mandate is implemented, the cost may be shifted from the public
payers to private payers. Individuals with private insurance tend to use that coverage before
using public programs, when they have access to both.
This program may shift costs from current nonprofit efforts to private insurance.
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V. Medical Efficacy
C.
1.

The Medical Efficacy of Mandating the Benefit
The contribution of the benefit to the quality of patient care and the health status of the
population, including any research demonstrating the medical efficacy of the treatment
or service compared to the alternative of not providing the treatment or service.

There are no alternatives for the current mouth swab testing. The swab testing is effective in
identifying potential donors, which increases the number of transplants that are possible. The
sooner a donor can be located the more effective the transplant may be.
2.

If the legislation seeks to mandate coverage of an additional class of practitioners:

This is not applicable.
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VI. Balancing the Effects
D.
1.

The Effects of Balancing the Social, Economic, and Medical Efficacy Considerations
The extent to which the need for coverage outweighs the cost of mandating the benefit
for all policyholders.

Bone marrow transplantations (BMT) are procedures that restore stem cells that have been
destroyed by illness, high doses of chemotherapy and/or radiation therapy. For patients
diagnosed with leukemia, lymphoma and other life-threatening diseases, a bone marrow
transplant may be their best or only hope for a cure. Yet 70% of patients who need a transplant
23
do not have a matching donor in their family and rely on finding a donor outside of their

family.
Currently there are other agencies that run donor drives and cover the cost of testing, but their
continued funding is not guaranteed.
2.

The extent to which the problem of coverage can be resolved by mandating the
availability of coverage as an option for policyholders.

It is likely that only those who would benefit from the services would purchase the coverage.
This would result in an alternative coverage that would cost more than the additional cost of
services because of the administrative charges that would be added to benefit costs. This cost
would be reduced if the option was only available when the coverage was initially purchased,
but it would then be less effective because many individuals would not anticipate needing the
coverage and, therefore, would not purchase it.
3.

The cumulative impact of mandating this benefit in combination with existing mandates
on costs and availability of coverage.

The estimated cost of current Maine mandates is detailed in Appendix C. For most of these
mandates, our estimate is based on the net impact on premiums as estimated at the time the
mandate was enacted. Four of the mandates – mental health, substance abuse, chiropractic,
and screening mammograms – require carriers to report annually the amount of claims paid for
these benefits and the estimates are based on that data. The true cost for the Maine mandates
23

Be the Match, How We Help Patients, Accessed 1/18/14, http://bethematch.org/About-Us/How-we-help-patients/
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are impacted by the fact that:
1.

Some services would be provided and reimbursed in the absence of a mandate.

2. Certain services or providers will reduce claims in other areas.
3. Some mandates are required by Federal law.
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VII. Appendices
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Appendix A: Letter from the Committee on I nsurance and Financial Services with Proposed
Legislation
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126th MAINE LEGISLATURE
SECOND REGULAR SESSION-2014
Legislative Document

No. 1600

H.P. 1172
House of Representatives, December 30, 2013
An Act To Require Health Insurers To Provide Coverage for
Human Leukocyte Antigen Testing To Establish Bone Marrow
Donor Transplantation Suitability
Approved for introduction by a majority of the Legislative Council pursuant to Joint Rule
203.
Received by the Clerk of the House on December 23, 2013. Referred to the Committee on
Insurance and Financial Services pursuant to Joint Rule 308.2 and ordered printed pursuant to
Joint Rule 401.
MILLICENT M. MacFARLAND
Clerk
Presented by Representative RANKIN of Hiram.
Cosponsored by Senator LANGLEY of Hancock and
Representatives: BEAVERS of South Berwick, BECK of Waterville, COOPER of Yarmouth,
DAUGHTRY of Brunswick, GATTINE of Westbrook, KINNEY of Limington, KORNFIELD
of Bangor, LONGSTAFF of Waterville, NADEAU of Winslow, PLANTE of Berwick,
THERIAULT of Madawaska, Senators: MILLETT of Cumberland, PATRICK of Oxford.
1
2
3
4
5
6

Be it enacted by the People of the State of Maine as follows:

Sec. 1. 24 MRSA §2317-B, sub-§12-I is enacted to read:
12-I. Title 24-A, sections 2769, 2847-U and 4260. Coverage for the cost of testing
for bone marrow donation suitability, Title 24-A, sections 2769, 2847-U and 4260;

Sec. 2. 24-A MRSA §2769 is enacted to read:
§2769. Coverage for the cost of testing for bone marrow donation suitability

7
8
9
10

1. Required coverage. All individual health insurance policies and contracts must
provide coverage for laboratory fees up to $150 arising from human leukocyte antigen
testing performed to establish bone marrow transplantation suitability in accordance with
the following requirements:

11
12
13

A. The individual covered under the policy or contract must meet the criteria for
testing established by the National Marrow Donor Program, or its successor
organization;

14
15
16

B. The testing must be performed in a facility that is accredited by a national
accrediting body with requirements that are substantially equivalent to or more
stringent than those of the College of American Pathologists and is certified under the
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17
18

federal Clinical Laboratories Improvement Act of 1967, 42 United States Code,
Section 263a; and

19
20
21
22
23

C. At the time of the testing, the individual covered under the policy or contract must
complete and sign an informed consent form that authorizes the results of the test to
be used for participation in the National Marrow Donor Program, or its successor
organization, and acknowledges a willingness to be a bone marrow donor if a suitable
match is found.

24
25
26
27

2. Prohibition. A testing facility may not bill, charge, collect a deposit from, seek
payment or reimbursement from or seek recourse against an individual covered under the
policy or contract or a person acting on behalf of the individual for any portion of the
laboratory fees.

28

Sec. 3. 24-A MRSA §2847-U is enacted to read:

29

§2847-U. Coverage for the cost of testing for bone marrow donation suitability

30
31
32
33

1. Required coverage. All group health insurance policies, contracts and
certificates must provide coverage for laboratory fees up to $150 arising from human
leukocyte antigen testing performed to establish bone marrow transplantation suitability
in accordance with the following requirements:

34
35
36

A. The individual covered under the policy, contract or certificate must meet the
criteria for testing established by the National Marrow Donor Program, or its
successor organization;
Page 1 - 126LR2402(01)-1
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1
2
3
4
5

B. The testing must be performed in a facility that is accredited by a national
accrediting body with requirements that are substantially equivalent to or more
stringent than those of the College of American Pathologists and is certified under the
federal Clinical Laboratories Improvement Act of 1967, 42 United States Code,
Section 263a; and

6
7
8
9
10

C. At the time of the testing, the individual covered under the policy, contract or
certificate must complete and sign an informed consent form that authorizes the
results of the test to be used for participation in the National Marrow Donor Program,
or its successor organization, and acknowledges a willingness to be a bone marrow
donor if a suitable match is found.

11
12
13
14

2. Prohibition. A testing facility may not bill, charge, collect a deposit from, seek
payment or reimbursement from or seek recourse against an individual covered under the
policy, contract or certificate or a person acting on behalf of the individual for any portion
of the laboratory fees.

15

Sec. 4. 24-A MRSA §4260 is enacted to read:

16

§4260. Coverage for the cost of testing for bone marrow donation suitability

17
18
19
20

1. Required coverage. All individual and group health maintenance organization
contracts must provide coverage for laboratory fees up to $150 arising from human
leukocyte antigen testing performed to establish bone marrow transplantation suitability
in accordance with the following requirements:

21
22

A. The individual covered under the contract must meet the criteria for testing
established by the National Marrow Donor Program, or its successor organization;

23
24
25
26
27

B. The testing must be performed in a facility that is accredited by a national
accrediting body with requirements that are substantially equivalent to or more
stringent than those of the College of American Pathologists and is certified under the
federal Clinical Laboratories Improvement Act of 1967, 42 United States Code,
Section 263a; and

28
29
30
31
32

C. At the time of the testing, the individual covered under the contract must complete
and sign an informed consent form that authorizes the results of the test to be used for
participation in the National Marrow Donor Program, or its successor organization,
and acknowledges a willingness to be a bone marrow donor if a suitable match is
found.

33
34
35
36

2. Prohibition. A testing facility may not bill, charge, collect a deposit from, seek
payment or reimbursement from or seek recourse against an individual covered under the
contract or a person acting on behalf of the individual for any portion of the laboratory
fees.

37
38
39

Sec. 5. Exemption from review. Notwithstanding the Maine Revised Statutes,
Title 24-A, section 2752, this Act is enacted without review and evaluation by the
Department of Professional and Financial Regulation, Bureau of Insurance.
Page 2 - 126LR2402(01)-1
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Page 3 - 126LR2402(01)-1

1
2
3
4
5

Sec. 6. Application. The requirements of this Act apply to all policies, contracts
and certificates subject to this Act that are executed, delivered, issued for delivery,
continued or renewed in this State on or after January 1, 2015. For purposes of this Act,
all contracts are deemed to be renewed no later than the next yearly anniversary of the
contract date.

6

SUMMARY

7
8
9

This bill requires health insurance coverage for laboratory fees up to $150 arising
from human leukocyte antigen testing performed to establish bone marrow
transplantation suitability.
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Appendix B: Cumulative I mpact of Mandates

Bureau of Insurance
Cumulative Impact of Mandates in Maine
Report for the Year 2012
This report provides data for medical insurance coverage of mandates as required by 24-A M.R.S.A.
§2752 and compiled by the Bureau of Insurance. While some data was provided through annual mandate
reports by insurers, other figures were estimated as a part of the proposed mandates study. The following
provides a brief description of each state mandate and the estimated claim cost as a percentage of
premium. Many of these mandates are now required by the federal Affordable Care Act (ACA). In
addition, the ACA requires benefits covered by the benchmark plan which includes all state mandates to
be covered by all individual and small group plans effective January 1, 2014. A summary chart is provided
at the end of this report.
Mental Health (Enacted 1983)
Mental health parity in Maine for listed conditions became effective July 1, 1996, and was expanded effective
October 1, 2003. The percentage of mental health claims paid has been tracked since 1984 and has historically
been between 3% and 4% of total group health claims and was reported as 3.3% in 2012. Mental health claims
stayed below 3.5%, despite the fact that an expansion of the list of conditions for which parity is required was
fully implemented in 2005. Mental health coverage is included in the essential health benefits for individual and
small group plans beginning 2014. This report includes claims as paid under the law requirements for 2012.
Individual mental health claims were only 1.9% in 2012 as a mandated offer. We have assumed that individual
mental health claims will increase under ACA and will be similar to group claims in 2014.


Substance Abuse (Enacted 1983)
The state mandate required the provision of benefits for alcoholism and drug dependency and applied only to
groups of more than 20. Effective October 1, 2003, substance abuse was added to the list of mental health
conditions for which parity is required. Effective on January 1, 2014 the federal Affordable Care Act requires
substance abuse treatment benefits for individual and small group plans as part of the essential health benefits.


The percentage of claims paid has been tracked since 1984. For 2012, substance abuse claims paid were 0.7% of
the total group health claims. Despite implementation of the parity requirement, there was a long-term decrease
in the percentage, likely due to utilization review, which sharply reduced the incidence of inpatient care. We
estimate substance abuse claims will remain at the current levels going forward.
Chiropractic (Enacted 1986)
This mandate generally requires coverage for the services of chiropractors to the extent that the same services
would be covered if performed by a physician. Using annual experience reports from the carriers, the percentage
of claims paid has been tracked since 1986 and, in 2012, was 1.0% of total health claims. The level has typically
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been lower for individual than for group. We estimate the current levels going forward. Although it is likely that
some of these costs would have been covered even in the absence of a mandate, we have no basis for estimating
how much. We have included the entire amount, thereby overstating the impact of the mandate to some extent.
Screening Mammography (Enacted 1990)
This mandate requires that benefits be provided for screening mammography. The U.S. Preventive Services Task
force has recommended that screening mammograms begin at a later age and be done less frequently. While it is
possible this will lead to reduced utilization, the American Cancer Society, The American College of
Obstetricians and Gynecologists, and many oncologists have not accepted these recommendations. We, therefore,
estimate the current level of 0.71% in all categories going forward. Coverage is required by ACA for preventive
services.


Dentists (Enacted 1975)
This mandate requires coverage for dentists’ services to the extent that the same services would be covered if
performed by a physician. It does not apply to HMOs. A 1992 study done by Milliman and Robertson for the
Mandated Benefits Advisory Commission estimated that these claims represent 0.5% of total health claims and
that the actual impact on premiums is "slight." It is unlikely that this coverage would be excluded in the absence
of a mandate. We include 0.1% as an estimate.


Breast Reconstruction (Enacted 1998)
This mandate requires coverage for reconstruction of both breasts to produce a symmetrical appearance after a
mastectomy. At the time this mandate was being considered in 1995, one carrier estimated the cost at $0.20 per
month per individual. We do not have a more recent estimate. We include 0.02% in our estimate of the maximum
cumulative impact of mandates.


Errors of Metabolism (Enacted 1995)
This mandate requires coverage for metabolic formula and up to $3,000 per year for prescribed modified lowprotein food products. At the time this mandate was being considered in 1995, Blue Cross estimated the cost at
$0.10 per month per individual. We do not have a more recent estimate. We include 0.01% in our estimate.


Diabetic Supplies (Enacted 1996)
This mandate requires that benefits be provided for medically necessary diabetic supplies and equipment. Based
on data collected in 2006, most carriers reported that there would be no cost increase or an insignificant cost
increase because they already provide this coverage. Based on our report we estimate 0.2%.


Minimum Maternity Stay (Enacted 1996)
This mandate requires that if a policy provides maternity benefits, the maternity (length of stay) and newborn
care benefits must be provided in accordance with “Guidelines for Prenatal Care.” Based on carrier responses
indicating that they did not limit maternity stays below those recommended, we estimate no impact.
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Pap Smear Tests (Enacted 1996)
This mandate requires that benefits be provided for screening Pap smear tests. HMOs would typically cover these
costs and, for non-HMO plans, the relatively small cost of this test would not in itself satisfy the deductible, so
there would be no cost unless other services were also received. We estimate a negligible impact of 0.01%.
Coverage is required by ACA for preventive services.
Annual GYN Exam Without Referral (Enacted 1996)
This mandate only affects HMO plans and similar plans, and it requires the provision of benefits for annual
gynecological exams without prior approval from a primary care physician. To the extent the Primary Care
Physician (PCP) would, in absence of this law, have performed the exam personally rather than referring to an
OB/GYN, the cost may be somewhat higher; therefore, we include 0.1%.


Breast Cancer Length of Stay (Enacted 1997)
This mandate requires that benefits for breast cancer treatment be provided for a medically appropriate period of
time as determined by the physician in consultation with the patient. Our report estimated a cost of 0.07% of
premium.


Off-label Use Prescription Drugs (Enacted 1998)
This mandate requires coverage of off-label prescription drugs in the treatment of cancer, HIV, and AIDS. Our
1998 report stated a "high-end cost estimate" of about $1 per member per month (0.6% of premium) if it is
assumed there is currently no coverage for off-label drugs. Because the HMOs claimed to already cover off-label
drugs, in which case there would be no additional cost; and, providers testified that claims have been denied on
this basis, we include half this amount, or 0.3%.


Prostate Cancer (Enacted 1998)
This mandate requires prostate cancer screenings if recommended by a physician, at least once a year for men 50
years of age or older until a man reaches the age of 72. No increase in premiums should be expected for the
HMOs that provide the screening benefits currently as part of their routine physical exam benefits. Our report
estimated additional claims cost for non-HMO plans would approximate $0.10 per member per month. With the
inclusion of administrative expenses, we would expect a total cost of approximately $0.11 per member per
month, or approximately 0.07% of total premiums.


Nurse Practitioners and Certified Nurse Midwives (Enacted 1999)
This law mandates coverage for nurse practitioners and certified nurse midwives and allows nurse practitioners
to serve as primary care providers. This mandate is estimated to increase premium by 0.16%.


Coverage of Contraceptives (Enacted 1999)
This mandate requires health plans that cover prescription drugs to cover contraceptives. Our report estimated an
increase of premium of 0.8%.
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Registered Nurse First Assistants (Enacted 1999)
This mandate requires health plans that cover surgical first assistants to cover registered nurse first assistants if
an assisting physician would be covered. No material increase in premium is expected.


Access to Clinical Trials (Enacted 2000)
This mandate requires that coverage be provided for an eligible enrollee to participate in approved clinical trials.
Our report estimated a cost of 0.19% of premium.


Access to Prescription Drugs (Enacted 2000)
This mandate only affects plans with closed formularies. Our report concluded that enrollment in such plans is
minimal in Maine and therefore the mandate will have no material impact on premiums.


Hospice Care (Enacted 2001)
No cost estimate was made for this mandate because the Legislature waived the requirement for a study. Because
carriers generally covered hospice care prior to the mandate, we assume no additional cost.


Access to Eye Care (Enacted 2001)
This mandate affects plans that use participating eye care professionals. Our report estimated a cost of 0.04% of
premium.


Dental Anesthesia (Enacted 2001)
This mandate requires coverage for general anesthesia and associated facility charges for dental procedures in a
hospital for certain enrollees for whom general anesthesia is medically necessary. Our report estimated a cost of
0.05% of premium.


Prosthetics (Enacted 2003)
This mandate requires coverage for prosthetic devices to replace an arm or leg. Our report estimated a cost of
0.03% of premium for groups over 20, and a cost of 0.08% of premium for small employer groups and
individuals.


LCPCs (Enacted 2003)
This mandate requires coverage of licensed clinical professional counselors. Our report on mental health parity
indicated no measurable cost impact for coverage of LCPCs.


Licensed Pastoral Counselors and Marriage & Family Therapists (Enacted 2005)
This mandate requires coverage of licensed pastoral counselors and marriage & family therapists. Our report
indicated no measurable cost impact for this coverage.
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Hearing Aids (Enacted 2007)
This mandate requires coverage for $1,400 for each ear every 36 months for children age 18 and under. The
mandate was phased-in between 2008 and 2010, and our report estimated a cost of 0.1% of premium.


Infant Formulas (Enacted 2008)
This mandate requires coverage for amino acid-based elemental infant formulas for children two years of age and
under, regardless of delivery method. This mandate is effective January 2009, and our report estimated a cost of
0.1% of premium.


Colorectal Cancer Screening (Enacted 2008)
This mandate requires coverage for colorectal cancer screening for persons fifty years of age or older, or less
than 50 years of age and at high risk for colorectal cancer according to the most recently published colorectal
cancer screening guidelines of a national cancer society. This mandate is effective January 2009. No carriers
stated they denied coverage prior to this mandate; therefore, our report estimated no impact on premium.


Independent Dental Hygienist (Enacted 2009)
This mandate requires individual dental insurance or health insurance that includes coverage for dental services
to provide coverage for dental services performed by an independent practice dental hygienist. This mandate
applies only to policies with dental coverage; therefore, there is no estimated impact on medical plan premiums.


Autism Spectrum Disorders (Enacted 2010)
This mandate requires all contracts to provide coverage for the diagnosis and treatment of autism spectrum
disorders for individuals five years of age or under. Coverage may be limited for applied behavior analysis to
$36,000 per year. This mandate is effective January 2011, and our 2009 report estimated a cost of 0.7% of
premium once the mandate is fully implemented if it included those under age 21. Because the current mandate
only applies to those up to age five, the estimate was reduced to 0.3% of premium.


Children’s Early Intervention Services (Enacted 2010)
This mandate requires all contracts to provide coverage for children’s early intervention services from birth to 36
months for a child identified with a developmental disability or delay. Benefits may be limited to $3,200 per
year. This mandate is effective January 2011, and our report estimated a cost of 0.05% of premium.
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COST OF EXISTING MANDATED HEALTH INSURANCE BENEFITS

Year
Enacted

1975
1983

Benefit
Must include benefits for dentists’ services to the extent that
the same services would be covered if performed by a
physician.
Benefits must be included for treatment of alcoholism and
drug dependency.

Type of Contract
Affected

All Contracts
0.10%
All Contracts

1975
1983
1995
2003

Benefits must be included for Mental Health Services,
including psychologists and social workers.

1986
1994
1995
1997

Benefits must be included for the services of chiropractors to
the extent that the same services would be covered by a
physician. Benefits must be included for therapeutic, adjustive
and manipulative services. HMOs must allow limited selfreferred for chiropractic benefits.

1990
1997

Benefits must be made available for screening mammography.

1995

Must provide coverage for reconstruction of both breasts to
produce symmetrical appearance according to patient and
physician wishes.

All Contracts

1995

Must provide coverage for metabolic formula and up to
$3,000 per year for prescribed modified low-protein food
products.

All Contracts

1996

If policies provide maternity benefits, the maternity (length of
stay) and newborn care benefits must be provided in
accordance with “Guidelines for Prenatal Care.”

All Contracts

1996
1996
1996
1997
1998
1998

Est. Maximum
Cost as % of
Premium

0.70%

Groups

Benefits must be provided for medically necessary equipment
and supplies used to treat diabetes and approved selfmanagement and education training.
Benefits must be provided for screening Pap tests.
Benefits must be provided for annual gynecological exam
without prior approval of primary care physician.
Benefits provided for breast cancer treatment for a medically
appropriate period of time determined by the physician in
consultation with the patient.
Coverage required for off-label use of prescription drugs for
treatment of cancer, HIV, or AIDS.
Coverage required for prostate cancer screening.

3.30%

Individual

3.30%

Group

1.0%

Individual

0.50%

Group

0.71%

Individual

0.71%

0.02%

0.01%

0
All Contracts
0.20%
0.01%

All
Group managed care

--

All Contracts
0.07%
All Contracts
All Contracts

0.30%
0.07%
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1999

Coverage of nurse practitioners and nurse midwives and
allows nurse practitioners to serves as primary care providers.

All Managed Care
Contracts

1999
1999
2000

Prescription drug must include contraceptives.
Coverage for registered nurse first assistants.
Access to clinical trials.

2000

Access to prescription drugs.

2001

Coverage of hospice care services for terminally ill.

2001

Access to eye care.

All Contracts
All Contracts
All Contracts
All Managed Care
Contracts
All Contracts
Plans with
participating eye care
professionals

2001

Coverage of anesthesia and facility charges for certain dental
procedures.

2003

Coverage for prosthetic devices to replace an arm or leg

2003

Coverage of licensed clinical professional counselors
Coverage of licensed pastoral counselors and marriage &
family therapists
Coverage of hearing aids for children
Coverage for amino acid-based elemental infant formulas
Coverage for colorectal cancer screening
Coverage for independent dental hygienist
Coverage for autism spectrum
Coverage for children’s early intervention services
Total cost for groups larger than 20:
Total cost for groups of 20 or fewer:
Total cost for individual contracts:

2005
2007
2008
2008
2009
2010
2010

All Contracts
Groups >20
All other
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts

-0.80%
0
0.19%
0
0

0
0.05%
0.03%
0.08%
0
0
0.1%
0.1%
0
0
0.3%
0.05%
8.11%
8.16%
7.66%
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